A Phase 2b, Randomised, Double-Blind, Placebo-Controlled Dose Range-Finding Study to Assess Efficacy and Safety of Multiple Dose Levels of Inhaled AZD8630 Given Once Daily for 12 Weeks in Adults With Uncontrolled Asthma at Risk of Exacerbations (LEVANTE)
Latest Information Update: 19 Jun 2025
At a glance
- Drugs AZD 8630 (Primary)
- Indications Asthma
- Focus Therapeutic Use
- Acronyms LEVANTE
- Sponsors AstraZeneca
Most Recent Events
- 08 Nov 2024 Planned End Date changed from 7 Apr 2026 to 6 Apr 2026.
- 08 Nov 2024 Planned primary completion date changed from 30 Mar 2026 to 18 Mar 2026.
- 12 Sep 2024 Planned End Date changed from 3 Apr 2026 to 7 Apr 2026.